This supply is part of CEPI's efforts to rapidly speed up the vaccine development timeline through making progress on manufacturing in parallel with the clinical development of COVID-19 vaccine candidates.
The WHO and its partners, including the Coalition for Epidemic Preparedness Innovations (CEPI), estimate that it will cost $18.1 billion to purchase and deliver the two billion doses of vaccine, which it will distribute to "at risk" populations, typically consisting of health care workers, the elderly and those with chronic conditions.
The first ones to get the vaccine, which has been tested and approved for emergency use, would most likely be the people of the country where it has been developed - meaning those in the USA and the UK. The clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%.
Soumya Swaminathan, the WHO's chief scientist said that Moderna's COVID-19 vaccine candidate was also "not far behind" Astrazeneca's, among more than 200 candidates, 15 of which have entered clinical trials.
Black Lives Matter demonstration in Lismore
Newsome told The Epoch Times that he feels Trump "is trying to get reelected and he'll say and do anything". Several restaurant patrons raised their hands when asked to do so by the Black Lives Matter activists.
The clinical trial process is divided into three phases. The CNBG is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries.
If things go according to the plan (which they have, till now), both vaccines are likely to be tested/approved for distribution by year-end.
The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford.
Chinese scientists and companies have tested six potential vaccines in clinical trials in China, including one vector, four inactivated and one recombinant protein vaccine.